欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
RKO人结肠腺癌细胞(STR鉴定)[套餐促销]
英文名:RKO
货号:ZQ0323
价格:¥1350.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

RKO人结肠腺癌细胞(STR鉴定)[套餐促销]

¥1350.00
+

RKO人结肠腺癌细胞专用培养基

¥350.00 ¥480.00

配套完培,组合使用,省时省力

=

细胞套餐惊爆价

¥1700 ¥1980.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

RKO人结肠腺癌细胞

货号

ZQ0323

产品介绍

RKO细胞是一种广泛应用于结肠癌相关研究的人类结直肠癌细胞系。它们来源于一种中等分化的结肠癌腺癌,其含有野生型P53,但缺乏人甲状腺受体核受体(h-TR beta 1)。 RKO细胞的P53蛋白的水平高于RKO-E6细胞。 RKO细胞系是RKO-E6和RKO-AS45-1的亲本细胞系。 该细胞系在裸鼠中成瘤,且在软琼脂中形成集落。RKO是一个低分化的结肠癌细胞系。这一特性使得RKO细胞对于研究p53功能以及结直肠癌中DNA修复和凋亡的细胞机制特别有价值。
RKO细胞表现出上皮形态,并以其遗传稳定性和对各种遗传和药理操作的反应性为特征。它被用于研究涉及癌症进展的分子途径,包括细胞周期调节、信号转导和转移。该细胞提供了各种基因和环境因素在结直肠癌发展中的作用的见解,并为测试抗癌药物的功效提供了一个平台。此外,该细胞被用于探索癌细胞与其微环境之间的复杂相互作用,以及对肿瘤细胞的免疫反应。它对化疗药物和放疗的敏感性使它适合用于药物发现和开发,有助于确定潜在的治疗靶点和评估结直肠癌的新治疗策略。总的来说,RKO细胞是结肠直肠癌研究的基础资源,对我们对疾病分子生物学的理解做出了重大贡献,并有助于开发更有效的治疗方法。

种属

性别/年龄

 ***

组织

结肠

疾病

细胞类型

肿瘤细胞 

形态学

上皮

生长方式

贴壁

倍增时间

大约21~36.34小时 

培养基和添加剂

MEM(含NEAA)(中乔新舟  货号:ZQ-300)+10%FBS(中乔新舟  货号:ZQ500-A+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0323

生物安全等级

BSL-1

STR位点信息

釉原蛋白:X
D5S818:11,13
D13S317: 8,11
D7S820: 8,10
D16S539: 13
vWA: 16,22
TH01: 6,10
TPOX: 11
CSF1PO: 8,10
D19S433: 14
D21S11: 27,30
D18S51: 11,12 

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

 ***

基因表达

 ***

保藏机构

ATCC; CRL-2577

供应限制

仅供科研使用

货号

ZQ0323

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


PubMed=7329817
Brattain M.G., Brattain D.E., Fine W.D., Khaled F.M., Marks M.E., Kimball P.M., Arcolano L.A., Danbury B.H.
Initiation and characterization of cultures of human colonic carcinoma with different biological characteristics utilizing feeder layers of confluent fibroblasts.
Oncodev. Biol. Med. 2:355-366(1981)


PubMed=6437669; DOI=10.1007/BF00048384
Brattain M.G., Levine A.E., Chakrabarty S., Yeoman L.C., Willson J.K.V., Long B.
Heterogeneity of human colon carcinoma.
Cancer Metastasis Rev. 3:177-191(1984)


PubMed=2835152
Boyd D., Florent G., Kim P., Brattain M.G.
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Cancer Res. 48:3112-3116(1988)


PubMed=2253215
Baker S.J., Preisinger A.C., Jessup J.M., Paraskeva C., Markowitz S.D., Willson J.K.V., Hamilton S.R., Vogelstein B.
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
Cancer Res. 50:7717-7722(1990)


PubMed=8387205; DOI=10.1073/pnas.90.9.3988
Kessis T.D., Slebos R.J.C., Nelson W.G., Kastan M.B., Plunkett B.S., Han S.M., Lorincz A.T., Hedrick L., Cho K.R.
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.
Proc. Natl. Acad. Sci. U.S.A. 90:3988-3992(1993)


PubMed=7798274; DOI=10.1016/S0021-9258(18)31687-9
Carrier F., Smith M.L., Bae I., Kilpatrick K.E., Lansing T.J., Chen C.-Y., Engelstein M., Friend S.H., Henner W.D., Gilmer T.M., Kastan M.B., Fornace A.J. Jr.
Characterization of human Gadd45, a p53-regulated protein.
J. Biol. Chem. 269:32672-32677(1994)


PubMed=7761852; DOI=10.1126/science.7761852
Markowitz S.D., Wang J., Myeroff L.L., Parsons R., Sun L.-Z., Lutterbaugh J.D., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., Brattain M.G., Willson J.K.V.
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.
Science 268:1336-1338(1995)


PubMed=7824277
Eshleman J.R., Lang E.Z., Bowerfind G.K., Parsons R., Vogelstein B., Willson J.K.V., Veigl M.L., Sedwick W.D., Markowitz S.D.
Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.
Oncogene 10:33-37(1995)


PubMed=9515795
Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Cancer Res. 58:1130-1134(1998)


PubMed=9715273; DOI=10.1038/sj.onc.1201986
Eshleman J.R., Casey G., Kochera M.E., Sedwick W.D., Swinler S.E., Veigl M.L., Willson J.K.V., Schwartz S., Markowitz S.D.
Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53.
Oncogene 17:719-725(1998)


PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)


PubMed=12615714
Hempen P.M., Zhang L., Bansal R.K., Iacobuzio-Donahue C.A., Murphy K.M., Maitra A., Vogelstein B., Whitehead R.H., Markowitz S.D., Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
Cancer Res. 63:994-999(2003)


PubMed=16418264; DOI=10.1073/pnas.0510146103
Liu Y., Bodmer W.F.
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)


PubMed=16854228; DOI=10.1186/1476-4598-5-29
Bandres Elizalde E.M., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.
Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.
Mol. Cancer 5:29.1-29.10(2006)


PubMed=17363507; DOI=10.1158/1535-7163.MCT-06-0555
Wang J., Kuropatwinski K., Hauser J., Rossi M.R., Zhou Y.-F., Conway A., Kan J.L.C., Gibson N.W., Willson J.K.V., Cowell J.K., Brattain M.G.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Mol. Cancer Ther. 6:1143-1150(2007)


PubMed=18258742; DOI=10.1073/pnas.0712176105
Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192
Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Cancer Res. 70:5901-5911(2010)


PubMed=20606684; DOI=10.1038/sj.bjc.6605780
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Br. J. Cancer 103:340-346(2010)


PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=24042735; DOI=10.1038/oncsis.2013.35
Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.
Epigenetic and genetic features of 24 colon cancer cell lines.
Oncogenesis 2:e71.1-e71.8(2013)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号